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The International Working Group on the Diabetic Foot (IWGDF) has published 
evidence-based guidelines on the prevention and management of diabetic foot 
disease since 1999. This guideline is on the diagnosis, prognosis and management 
of peripheral artery disease in patients with foot ulcers and diabetes and updates 
the previous IWGDF guideline. 
Up to 50% of patients with diabetes and foot ulceration have concurrent 
peripheral artery disease (PAD), which confers a significantly elevated risk of 
adverse limb events and cardiovascular disease. We know that the diagnosis, 
prognosis and treatment of these patients are markedly different to patients with 
diabetes who do not have PAD and yet there are few good quality studies 
addressing this important sub-set of patients.  
We followed the GRADE methodology to devise clinical questions and critically 
important outcomes in the PICO format, to conduct a systematic review of the 
medical-scientific literature, and to write recommendations and their rationale. 
The recommendations are based on the quality of evidence found in the 
systematic review, expert opinion where evidence was not available, and a 
weighing of the benefits and harms, patient preferences, feasibility and 
applicability, and costs related to the intervention.  
We here present the updated 2019 guidelines on diagnosis, prognosis and 
management of PAD in patients with a foot ulcer and diabetes, and we suggest 




1. Examine the feet of all patients with diabetes annually for the presence 
of peripheral artery disease, even in the absence of foot ulceration. At a 
minimum, this should include taking a relevant history and palpating 
foot pulses. (Strength of the recommendation: Strong; Quality of the 
evidence: Low) 
2. Clinically examine (by relevant history and palpation of foot pulses) all 
patients with diabetes and foot ulceration for the presence of 
peripheral artery disease. (Strong; Low) 
3. As clinical examination does not reliably exclude peripheral artery 
disease (PAD) in most persons with diabetes and a foot ulcer, evaluate 
pedal Doppler arterial waveforms in combination with ankle systolic 
pressure and systolic ankle brachial index (ABI) or toe systolic pressure 
and toe brachial index (TBI) measurement. No single modality has been 
shown to be optimal and there is no definite threshold value above 
which PAD can reliably be excluded. However, PAD is a less likely 
diagnosis in the presence of ABI 0.9-1.3, toe brachial index ≥0.75 and 
triphasic pedal Doppler waveforms. (Strong; Low)  
4. Perform at least one of the following bedside tests in a patient with a 
diabetic foot ulcer and peripheral artery disease, any of which increases 
the pre-test probability of healing by at least 25%: a skin perfusion 
pressure ≥40 mmHg; a toe pressure ≥30 mmHg; or, a transcutaneous 
oxygen pressure (TcPO2) ≥25 mmHg. (strong; moderate)  
5. Use the WIfI (Wound/Ischaemia/foot Infection) classification system 
as a means to stratify amputation risk and revascularisation benefit in 
a patient with a diabetic foot ulcer and peripheral artery disease. 
(Strong; Moderate) 
6. Always consider urgent vascular imaging, and revascularisation, in a 
patient with a diabetic foot ulcer and an ankle pressure <50mmHg, ABI 
<0.5, a toe pressure <30 mmHg or a TcPO2 <25 mmHg. (Strong; Low)  
7. Always consider vascular imaging in patients with a diabetic foot ulcer, 
irrespective of the results of bedside tests, when the ulcer is not healing 
within 4-6 weeks despite good standard of care. (Strong; Low) 
8. Always consider revascularisation in a patient with a diabetic foot ulcer 
and peripheral artery disease, irrespective of the results of bedside 
tests, when the ulcer is not healing within 4-6 weeks despite optimal 
management. (Strong; Low). 
9. Do not assume diabetic microangiopathy, when present, is the cause of 
poor healing in patients with a diabetic foot ulcer, therefore always 
consider other possibilities for poor healing. (Strong; Low) 
10. Use any of the following modalities to obtain anatomical information 
when considering revascularising a patient’s lower extremity: colour 
Duplex ultrasound; computed tomographic angiography; magnetic 
resonance angiography; or, intra-arterial digital subtraction 
angiography. Evaluate the entire lower extremity arterial circulation 
with detailed visualisation of below-the-knee and pedal arteries, in an 
anteroposterior and lateral plane. (Strong; Low) 
11. When performing revascularisation in a patient with a diabetic foot 
ulcer, aim to restore direct blood flow to at least one of the foot arteries, 
preferably the artery that supplies the anatomical region of the ulcer. 
After the procedure, evaluate its effectiveness with an objective 
measurement of perfusion. (Strong; Low) 
12. As evidence is inadequate to establish whether an endovascular, open 
or hybrid revascularisation technique is superior, make decisions 
based on individual factors, such as morphological distribution of 
peripheral artery disease, availability of autogenous vein, patient co-
morbidities and local expertise. (Strong; Low) 
13. Any centre treating patients with a diabetic foot ulcer should have 
expertise in, and rapid access to facilities necessary to diagnose and 
treat, PAD, including both endovascular techniques and bypass surgery. 
(Strong; Low)  
14. Ensure that after a revascularisation procedure in a patient with a 
diabetic foot ulcer, the patient is treated by a multidisciplinary team as 
part of a comprehensive care plan. (Strong; Low) 
15. Urgently assess and treat patients with signs or symptoms of peripheral 
artery disease and a diabetic foot infection, as they are at particularly 
high risk for major limb amputation. (Strong; Moderate) 
16. Avoid revascularisation in patients in whom, from the patient’s 
perspective, the risk–benefit ratio for the probability of success of the 
procedure is unfavourable. (Strong; Low) 
17. Provide intensive cardiovascular risk management for any patient with 
diabetes and an ischaemic foot ulcer, including support for cessation of 
smoking, treatment of hypertension, control of glycaemia and 
treatment with a statin drug as well as low-dose clopidogrel or aspirin. 
(Strong; Low)  
 
Introduction 
The global burden of diabetes has increased rapidly over the past decade and 
many international bodies now consider diabetes a public health emergency. 
Health professionals and patients are becoming increasingly aware of the 
seriousness of diabetes-related complications. Yet despite substantial increase in 
awareness, the introduction of dedicated screening programmes and specialised 
interdisciplinary care teams in many developed countries, the number of people 
with diabetes has quadrupled since 1980 and the pooled estimate of worldwide 
prevalence of diabetes and foot ulceration is approximately 3% 1 in community-
based cohorts, with a wide variation in rates of major amputation across the world 
2.  
 
It is estimated that in middle and high income countries up to 50% of patients with 
diabetes and foot ulceration have underlying peripheral artery disease (PAD) 3 4, 
whereas neuropathic ulcers are possibly more prevalent in low income countries 
5 6. In patients with diabetes, PAD may remain undiagnosed until the patient 
presents with (severe) tissue loss, as many patients typically lack the classic 
preceding clinical symptoms of PAD such as claudication or rest pain 7 8. 
Diagnostic tests may be less reliable due to the presence of peripheral neuropathy, 
medial arterial calcification 9 and peripheral oedema. However, it is important to 
identify PAD in patients with diabetic foot ulceration (DFU) at the earliest possible 
stage, as the presence of PAD is associated with increased risk of non-healing 
ulcers, infection and major limb amputation, as well as an elevated risk of 
cardiovascular morbidity and overall mortality 10 11 12 13 14. The prognosis of a 
patient with diabetes, PAD and foot ulceration requiring amputation is worse than 
many common cancers – up to 50% of patients will not survive 5 years 4 15.  
 
There are several guidelines for the management of patients with PAD and chronic 
limb threatening ischaemia (CLTI). However, most studies reporting on PAD 
outcomes fail to include a diabetes sub-group, although it is likely that many of the 
included patients actually have diabetes. Moreover, many studies reporting on 
PAD and diabetes include only patients with intact feet, or do not adequately 
describe the presences of neuropathy, ulcer, infection or other contributing 
factors to poor outcomes 16. 
 
There is no doubt that patients with diabetes and PAD represent a special sub-
group. They tend to have a different clinical presentation, natural history and 
outcomes. Patients frequently present with severe tissue loss without significant 
symptoms, which may rapidly progress to limb loss; further characteristics are 
described in Table 1. As such, there is clearly a need for further research into this 
unique sub-group of patients with diabetes, foot ulceration and PAD in order that 
we may improve outcomes around the world. 
 
Table 1: 74 
Characteristics of PAD in people with diabetes (compared to people without diabetes) 
 More common  
 Affects younger individuals 
 Multi-segmental and bilateral 
 More distal  
 More medial calcification 
 Impaired collateral formation  
 Faster progress with higher risk of amputation  
 
 
This guideline is an update of the previous IWGDF Guideline on PAD 17, and is part 
of the IWGDF Guidelines on the prevention and management of diabetic foot 
disease. We aim to provide evidence-based recommendations on the diagnosis, 
prognosis, and management of PAD in patients with a foot ulcer and diabetes.  
 
Methods 
In this guideline we have followed the GRADE methodology, which is structured 
around clinical questions in the PICO-format (Patient-Intervention-Comparison-
Outcome), systematic searches and assessment of the available evidence, followed 
by developing recommendations and their rationale 18 19. 
 
First, a multidisciplinary working group of independent experts (the authors of 
this guideline) was installed by the IWGDF editorial board. The members of the 
working group devised the clinical questions, which were revised after 
consultation with external experts from various geographical regions and the 
IWGDF Editorial Board. The aim was to ensure the relevance of the questions for 
clinicians and other health care professionals in providing useful information on 
the diagnosis, prognosis and management of peripheral artery disease in persons 
with diabetes and a foot ulcer. We also formulated what we considered critically 
important outcomes relevant for daily care, using the set of outcomes defined by 
Jeffcoate et al. 16 as a reference guide.  
 
Second, we systematically reviewed the literature to address the agreed upon 
clinical questions. For each assessable outcome we graded the quality of evidence 
based on the risk of bias of included studies, effect sizes, presence of inconsistency, 
and evidence of publication bias (the latter where appropriate). We then rated the 
quality of evidence as ‘high’, ‘moderate’ or ‘low’. The systematic review(s) 
supporting this guideline are published separately 20 21 22.  
 
Third, we formulated recommendations to address each clinical question. We 
aimed to be clear, specific and unambiguous on what we recommend, for which 
persons, and under what circumstances. Using the GRADE system we provided the 
rationale for how we arrived at each recommendation, based on the evidence from 
our systematic review(s) 20 21 22, expert opinion where evidence was not available, 
and a careful weighing of the benefits and harms, patient preferences, and 
financial costs (resource utilization) related to the intervention or diagnostic 
method 18 19. Based on these factors, we graded the strength of each 
recommendation as ‘strong’ or ‘weak’, and for or against a particular intervention 
or diagnostic method. All our recommendations (with their rationales) were 
reviewed by the same international experts who reviewed the clinical questions, 
as well as by the members of the IWGDF Editorial Board.  
 
We refer those seeking a more detailed description on the methods for developing 
and writing these guidelines to the ‘IWGDF Guidelines development and 




PICO: In a person with diabetes and no foot ulceration, which symptoms and signs 
(clinical examination) should clinicians examine in order to identify or exclude 
peripheral artery disease? 
 
Recommendation 1: Examine the feet of all patients with diabetes annually for 
the presence of peripheral artery disease, even in the absence of foot ulceration. 
At a minimum, this should include taking a relevant history and palpating foot 
pulses. (Strong; Low) 
 
Rationale 
This recommendation is in line with other (inter)national guidelines on the 
management of diabetes, recommending yearly screening for PAD in subjects with 
diabetes 24 25 26. In addition to absent foot pulses, specific clinical findings that alert 
the healthcare professional to the presence of PAD include the presence of femoral 
bruits and a slow venous filling time 27 8 . Symptoms and signs of PAD, such as 
claudication, absent pulses and a low ABI, were identified as predictors of future 
ulceration in a recent systematic review 28, however classical signs may be absent 
in patients with PAD and a DFU. Patients with diabetes and these signs of PAD 
should therefore be reviewed more frequently. Moreover, individuals with PAD 
have an elevated risk of other cardiovascular diseases, necessitating strategies to 
address these problems as well 29. 
 
 
PICO: In a person with diabetes and a foot ulcer, which symptoms and signs 
(clinical examination) should clinicians examine in order to identify or exclude 
peripheral artery disease? 
Recommendation 2: Clinically examine (by relevant history and palpation of foot 
pulses) all patients with diabetes and foot ulceration for the presence of 
peripheral artery disease. (Strong; Low) 
 
Rationale 
Few data exist about the accuracy of symptoms or clinical examination for the 
identification of PAD in patients with diabetes and foot ulceration. Although a 
properly performed medical history and clinical examination can suggest the 
presence of PAD in a patient with a foot ulcer, their sensitivity is too low to rule 
out PAD in all patients. Many patients with diabetes and PAD have few or atypical 
symptoms7 and in our experience, patients can have severe tissue loss with 
limited symptoms. The paucity of symptoms may be related to the presence of co-
existing neuropathy and loss of pain sensation. Foot temperature may be 
unreliable due to arterio-venous shunting resulting in a relatively warm foot 30. 
The palpation of foot pulses should form a key part of the initial clinical 
examination, however the presence of palpable foot pulses cannot be used in 
isolation to reliably exclude PAD. For example, in a screened primary care 
population of patients > 50 years more than two thirds of patients with PAD had 
a detectable pulse 31. Even in the hands of a skilled examiner, palpable pulses may 
be present despite the presence of significant ischaemia 32. Therefore, a more 
objective evaluation should be performed in all patients with a foot ulcer.  
 
 
PICO: In a person with diabetes and a foot ulcer which ‘bedside’ diagnostic 
procedure, alone or in combination, has the best performance in diagnosing or 
excluding peripheral artery disease? 
Recommendation 3: As clinical examination does not reliably exclude peripheral 
artery disease (PAD) in most persons with diabetes and a foot ulcer, evaluate 
pedal Doppler arterial waveforms in combination with ankle systolic pressure and 
systolic ankle brachial index (ABI) or toe systolic pressure and toe brachial index 
(TBI) measurement. No single modality has been shown to be optimal and there 
is no definite threshold value above which PAD can reliably be excluded. However, 
PAD is a less likely diagnosis in the presence of ABI 0.9-1.3, toe brachial index 
≥0.75 and triphasic pedal Doppler waveforms. (Strong; Low)  
 
Rationale 
In addition to clinical history and examination, an objective evaluation should be 
performed in all patients with a foot ulcer. As discussed in our systematic review 
20, an ABI (<0.9) is a useful test for the detection of PAD. However, an ABI >0.9 
does not rule out PAD. The majority of patients with PAD and a foot ulcer will have 
(autonomic) peripheral neuropathy, which is associated with medial wall 
calcification (Mönckeberg sclerosis) of the arteries in the lower leg, resulting in 
rigid arteries and an elevated ABI, adversely affecting the utility of the test 9. It 
should be noted that medial calcification does not necessarily cause arterial 
stenosis and reduced blood flow 33 29. The detection of a triphasic pedal Doppler 
arterial waveform with a handheld Doppler appears to provide stronger evidence 
for the absence of PAD. The same applies for measurement of a toe brachial index, 
which makes the presence of PAD unlikely if it is ≥0.75 20 and provides additional 
information compared to the ABI, particularly in patients with severe PAD below 
the ankle 34. Unfortunately, toe pressures may also be falsely elevated by the same 
factors that affect ABI (including digital artery calcification). There is insufficient 
evidence to support the use of a single bedside diagnostic test for PAD that may 
be used for all patients with diabetes and foot ulceration 35. However recent 
studies suggest that TBI and tibial waveforms (measured at the level of the medial 
malleolus, the dorsalis pedis and in the mid-calf for the peroneal artery) are the 
most useful non-invasive tests to select patients for diagnostic imaging 36 37. Using 
more than one test in parallel certainly improves diagnostic accuracy 35 38 39.  
 
There are no definitive data on the absolute threshold or ‘normal’ values of non-
invasive tests for people with diabetes and foot ulceration. Previous studies 
examining the use of bedside tests to diagnose PAD have used pre-determined 
threshold values, however there is no information available about other 
thresholds that may be of interest. We suggest that PAD is a less likely diagnosis 
in the presence of ABI 0.9-1.3, toe brachial index ≥0.75 and triphasic pedal 
Doppler waveforms, however this should be complimented by definitive imaging 
where uncertainty remains. 
 
All bedside techniques should be performed by trained healthcare professionals 
in a standardised manner. There is insufficient evidence to confidently 
recommend the use of any of the aforementioned bedside non-invasive diagnostic 
modalities over another for the detection of PAD. Healthcare professionals should 
be aware of the limitations of each modality and must decide which, either singly 






PICO: In a person with diabetes foot ulceration and PAD, which clinical signs, 
symptoms or non-invasive bedside tests may predict ulcer healing and 
amputation? 
 
Recommendation 4: Perform at least one of the following bedside tests in a 
patient with a diabetic foot ulcer and peripheral artery disease, any of which 
increases the pre-test probability of healing by at least 25%: a skin perfusion 
pressure ≥40 mmHg; a toe pressure ≥30 mmHg; or, a transcutaneous oxygen 
pressure (TcPO2) ≥25 mmHg. (strong; moderate)  
 
Recommendation 5: Use the WIfI (Wound/Ischaemia/foot Infection) 
classification system as a means to stratify amputation risk and revascularisation 
benefit in a patient with a diabetic foot ulcer and peripheral artery disease.  
(Strong; Moderate) 
 
Recommendation 6: Always consider urgent vascular imaging, and 
revascularisation, in a patient with a diabetic foot ulcer and an ankle pressure 
<50mmHg, ABI <0.5, a toe pressure <30 mmHg or a TcPO2 <25 mmHg. (Strong; 
Low)  
 
Recommendation 7: Always consider vascular imaging in patients with a 
diabetic foot ulcer, irrespective of the results of bedside tests, when the ulcer is 
not healing within 4-6 weeks despite good standard of care. (Strong; Low). 
 
Recommendation 8: Always consider revascularisation in a patient with a 
diabetic foot ulcer and peripheral artery disease, irrespective of the results of 
bedside tests, when the ulcer is not healing within 4-6 weeks despite optimal 
management. (Strong; Low). 
 
Recommendation 9: Do not assume diabetic microangiopathy, when present, is 
the cause of poor healing in patients with a diabetic foot ulcer, therefore always 
consider other possibilities for poor healing. (Strong; Low) 
 
Rationale 
In our systematic review, the most useful tests for predicting healing in an 
ulcerated foot were skin perfusion pressure (≥40 mmHg), toe pressure (≥30 
mmHg) and TcPO2 (≥25 mmHg) 21. All increased the pre-test probability of healing 
by at least 25% in one or more study. Given the variability of PAD in terms of its 
distribution, severity and symptoms, it is unsurprising that no single measure 
performed with consistent accuracy for the prediction of healing. Interpretation 
of the specific characteristics of PAD that predict healing, or failure to heal, of a 
diabetic foot ulcer should be taken in the context of the quality of the published 
literature, which is limited.  
 
Most available data in the literature are based on univariable analysis, and these 
PAD measures should all be interpreted in the context of other determinants of 
outcome. Given the relatively poor chance of healing and the increased risk of 
amputation in patients with a toe pressure<30mmHg or a TcPO2 <25mmHg, we 
suggest imaging and consideration of revascularisation in these patients. The ABI 
has very little value in predicting ulcer healing 40, but an ABI <0.5 and/or an ankle 
pressure <50mmHg does confer a higher risk of amputation. Urgent imaging and 
treatment should also be considered in patients with PAD and higher pressure 
levels, in the presence of other predictors of poor prognosis, including infection or 
large ulcer surface area 41. A recent study has suggested that perfusion 
angiography may predict early major amputation but this needs further 
confirmation 42. Finally, in light of their limited diagnostic and prognostic utility, 
none of the tests described earlier can completely rule out PAD as a cause of 
impaired wound healing in a foot ulcer that does not respond to optimal 
treatment. Vascular imaging should therefore be performed in these patients in 
order to determine if the patient would benefit from revascularisation. In an 
observational study, shorter time to revascularisation (<8 weeks) was associated 
with a higher probability of healing of ischaemic foot ulcers 43. Additionally, a 
recent retrospective study demonstrated that patients with diabetes who 
experienced a delay of greater than 2 weeks from presentation to 
revascularisation were at a significantly increased risk of limb loss 44. These 
studies suggest that an aggressive approach with early revascularisation might 
improve outcome but these procedures are not without risk as summarised below 
22. The zealous approach of ‘the sooner the better’ may be tempting, however this 
should be also mitigated by the finding that up to 50% of patients with DFU and 
PAD who do not undergo revascularisation may be expected to heal their foot 
ulcers 10. There is therefore no ‘one size fits all approach’ and each case should be 
evaluated on an individual basis. 
 
We recommend considering revascularisation in all patients with diabetes, PAD 
and a foot ulcer, irrespective of the results of bedside tests, when the ulcer does 
not improve within 4-6 weeks despite optimal management. Due to the multiple 
factors contributing to non-healing, it is impossible to determine the optimal 
duration of a trial of conservative management before considering imaging and 
vascular intervention. A post hoc analysis of a clinical trial suggested that a 4-week 
period is sufficient in patients with uncomplicated neuropathic foot ulcers to 
assess the likelihood of healing 45. For pragmatic reasons, based on expert opinion, 
we suggest considering vascular imaging and subsequent revascularisation in 
neuro-ischaemic ulcers that do not improve within 6 weeks and have no other 
likely cause of poor wound healing.  
 
Healing is related to the interplay of the severity of the perfusion deficit with other 
characteristics of the foot and the patient, such as amount of tissue loss, presence 
of infection, mechanical load on the ulcer, comorbidities such as heart failure and 
end-stage renal disease 46. As discussed in our IWGDF classification guideline 47, 
the Wound, Ischemia and Foot infection (WIfI) classification system can guide the 
clinician in estimating the risk of amputation and potential benefit of 
revascularisation. This system categorises the patient’s ulcer, severity of 
ischaemia based on non-invasive tests and the severity of infection based on the 
IWGDF/IDSA classification. The WIfI system was generated from expert 
consensus and subsequently validated in diabetes and non-diabetes 
populations48. The scoring system is summarised in Table 2, is discussed in our 
classification guideline, and is freely available to download as a calculator tool 47 
49. Finally, the chance of healing will be related to the subsequent quality of care, 
which should address any of these aforementioned problems. 
 
Table 2: 48 
Wound   
Grade DFU Gangrene 
0 
No ulcer No gangrene 
Clinical description: minor tissue loss. Salvageable with simple digital 
amputation (1 or 2 digits) or skin coverage. 
1 
Small, shallow ulcer(s) on distal leg or 
foot; no exposed bone, unless limited 
to distal phalanx 
No gangrene 
Clinical description: minor tissue loss. Salvageable with simple digital 
amputation (1 or 2 digits) or skin coverage. 
2 
Deeper ulcer with exposed bone, joint 
or tendon; generally not involving the 
heel; shallow heel ulcer, without 
calcaneal involvement 
Gangrenous changes limited to digits 
Clinical description: major tissue loss salvageable with multiple (≥3) digital 
amputations or standard transmetatarsal amputation (TMA) ± skin coverage. 
3 
Extensive, deep ulcer involving 
forefoot and/or midfoot; deep, full 
thickness heel ulcer ± calcaneal 
involvement 
Extensive gangrene involving forefoot 
and /or midfoot; full thickness 
heel necrosis 6 calcaneal involvement 
Clinical description: extensive tissue loss salvageable only with a complex foot 
reconstruction or non-traditional TMA (Chopart or Lisfranc); flap coverage or 
complex wound management needed for large soft tissue defect 
Ischemia    




Toe Pressure, Transcutaneous 
oxygen pressure 
(mmHg) 
0 ≥ 0.80 >100 ≥60 
1 0.6-0.79 70-100 40-59 
2 0.4-0.59 50-70 30-39 
3 ≤0.39 <50 <30 
Foot Infection 
Grade Clinical manifestations 
0 
No symptoms or signs of infection 
Infection present, as defined by the presence of at least 2 of the following items: 
 Local swelling or induration 
 Erythema >0.5 to ≤2 cm around the ulcer 
 Local tenderness or pain 
 Local warmth 
 Purulent discharge (thick, opaque to white, or sanguineous secretion) 
1 
Local infection involving only the skin and the subcutaneous tissue (without 
involvement of deeper tissues and without systemic signs as described below). 
Exclude other causes of an inflammatory response of the skin (e.g., trauma, gout, 
acute Charcot neuro-osteoarthropathy, fracture, thrombosis, venous stasis) 
2 
Local infection (as described above) with erythema >2 cm, or involving 
structures deeper than skin and subcutaneous tissues (e.g., abscess, 
osteomyelitis, septic arthritis, fasciitis), and 
No systemic inflammatory response signs (as described below) 
3 
Local infection (as described above) with the signs of SIRS, as manifested by 
two or more of the following: 
 Temperature >38ºC or <36ºC 
 Heart rate >90 beats/min 
 Respiratory rate >20 breaths/min or PaCO2 <32 mm Hg 
 White blood cell count >12,000 or <4000 cu/mm or 10% immature 
(band) forms 
SIRS = systemic inflammatory response signs 
 
In the past, microangiopathy was thought to be an important cause of poor healing 
of a diabetic foot ulcer. However, there is currently no evidence to support this 
notion, and PAD remains the most important cause of impaired perfusion of the 
foot in a patient with diabetes 50. However, it should be noted that PAD is not the 
only cause of reduced perfusion in a lower extremity because oedema and 
infection can also result in a decrease in tissue oxygenation, and these should all 




PICO: In a person with diabetes and foot ulceration, which diagnostic imaging 
modalities to obtain anatomical information are most useful when considering 
revascularisation? 
Recommendation 10: Use any of the following modalities to obtain anatomical 
information when considering revascularising a patient’s lower extremity: colour 
Duplex ultrasound; computed tomographic angiography; magnetic resonance 
angiography; or, intra-arterial digital subtraction angiography. Evaluate the entire 
lower extremity arterial circulation with detailed visualisation of below-the-knee 
and pedal arteries, in an anteroposterior and lateral plane. (Strong; Low) 
 
Rationale 
Deciding who needs lower limb arterial revascularisation and determining what 
procedure is the most appropriate to achieve revascularisation requires 
appropriate imaging to guide therapy. It is unacceptable to rely on clinical 
examination alone prior to performing a revascularisation procedure. Anatomical 
information on the arteries of the lower limb should be obtained to assess the 
presence, severity and distribution of arterial stenoses or occlusions. Obtaining 
detailed imaging of below-the-knee and pedal arteries, especially with a dedicated 
assessment of the pedal circulation, is critically important in patients with 
diabetes. Techniques to define the lower limb arterial system in patients with 
diabetes include Duplex ultrasound, magnetic resonance angiography, computed 
tomography angiography and digital subtraction angiography 50.  
 
Briefly, Colour Duplex ultrasound (CDUS) provides both anatomic details and a 
physiologic assessment of blood flow at specific arterial sites. By scanning 
sequentially from the abdominal to the tibial arteries, the entire lower extremity 
arterial circulation can be directly evaluated. However, diffuse multi-segmental 
involvement, calcification and oedema may hamper the investigation. CDUS has 
the advantage of being a non-invasive test but it requires sophisticated equipment 
and specialized expertise and is not appropriate as a routine screening test. In 
computed tomography angiography (CTA), an iodinated contrast medium is 
injected intravenously and the vascular tree from the level of the renal arteries 
down to the foot can be visualised. Severe calcification may hamper the evaluation 
of smaller arteries, especially in the lower leg. Further disadvantages are potential 
allergic reactions and the development of contrast-induced nephropathy, 
particularly in patients with pre-existing renal disease or cardiac failure. In 
contrast-enhanced magnetic resonance angiography (CE-MRA) gadolinium is 
used as contrast and with dedicated techniques images can be obtained from the 
abdominal aorta down to the foot. A major advantage of CE-MRA is the use of a 
contrast agent with low nephrotoxicity, disadvantages include the limited special 
resolution and artefacts because of previous stent placement. However, its use is 
limited in patients with implants, such as pacemakers and claustrophobia and in 
patients with severe renal insufficiency (creatinine clearance <30mL/min) use of 
gadolinium-containing contrast is (relatively) contraindicated because of the risk 
of developing nephrogenic systemic fibrosis. Newer non-gadolinium agents, such 
as ultrasmall superparamagnetic particles of iron oxide (which has a number of 
magnetic resonance applications), may be alternative and safer agents in patients 
with compromised renal function 53. 
 
Intra-arterial digital subtraction angiography is still regarded as the gold standard 
for arterial imaging because of its high spatial resolution. It has the advantage of 
allowing endovascular therapy during the same procedure but has the 
disadvantage of the use of an iodinated contrast medium and is an invasive 
procedure, associated with potential complications of arterial puncture.  
 
Healthcare professionals should be aware of these techniques and of their 
limitations in individual patients. The decision on which imaging modality to use 
will depend upon patient contraindications as well as local availability and 
expertise. 
 
PICO: What are the aims and methods of revascularisation and onward 
management in a person with diabetes, foot ulceration and PAD? 
Recommendation 11: When performing revascularisation in a patient with a 
diabetic foot ulcer, aim to restore direct blood flow to at least one of the foot 
arteries, preferably the artery that supplies the anatomical region of the ulcer. 
After the procedure, evaluate its effectiveness with an objective measurement of 
perfusion. (Strong; Low) 
 
Rationale 
The natural history of patients with diabetes, PAD and an ulcerated foot remains 
poorly defined, but in two studies reporting the outcomes of patients with 
diabetes and limb ischaemia who were not revascularised, the limb salvage rate 
was around 50% at 1 year 10 54. After a revascularisation procedure, most studies 
report limb salvage rates of 80–85% and ulcer healing in >60% at 12 months 22. 
The quality of evidence is generally low due to the poorly defined population 
cohorts, variability of indications for intervention and multiple potentially 
confounding factors. Patients undergoing revascularisation are at increased risk 
of peri-operative mortality and the highest risk group is those patients with 
diabetes, PAD and end-stage renal disease, who have a 5% peri-operative 
mortality, 40% 1-year mortality and 1-year limb salvage rates of around 70% 22.  
 
Historically, the aim of revascularisation in patients with PAD has been to achieve 
inline pulsatile flow to the foot, usually by targeting the best vessel available. 
However, more recently, the angiosome-directed approach has been advocated 
but remains a subject of much debate 55 56. According to this theory, the foot can 
be divided into three-dimensional blocks of tissue, each with its own feeding 
artery. Direct revascularisation would result in a restoration of pulsatile blood 
flow through the feeding artery to the area where the ulcer is located, while with 
indirect revascularisation flow is restored through collateral vessels deriving 
from neighbouring angiosomes. By targeting revascularisation at the vessel 
directly supplying the anatomical area (angiosome) of tissue loss, the theory is 
that this will be a more effective method of revascularisation than simply targeting 
the best vessel, which may not supply the area of tissue loss. A recent retrospective 
study of endovascular limb salvage attempts in patients with DFU suggested that 
indirect angiosome revascularisation was associated with poorer outcomes than 
direct revascularisation 57. However, due to lack of clear definitions and factors 
like selection bias, the effectiveness of the angiosome concept in patients with 
diabetes is unknown 58 59 60 55. Particularly in patients with diabetes who usually 
have poor collaterals, restoration of flow to an artery directly supplying the 
affected area seems the best approach during an endovascular procedure 56. 
Successfully opening one or more occluded vessels is not the same as a clinically 
successful procedure and before the procedure is terminated blood flow to the 
ulcer area should therefore be assessed. If feasible, opening multiple arteries may 
be useful provided at least one supplies the ischaemic area directly 55. 
 
The effectiveness of a revascularisation procedure should preferably be evaluated 
with objective perfusion measurements. We have not provided target perfusion 
pressures in this recommendation, as there is no robust evidence to support such 
an approach. We previously suggested revascularisation should achieve a 
minimum skin perfusion pressure of 40mmHg, toe pressure >30mmHg or TcPO2 
>25mmHg in order to be considered effective 17. However, we now recommend 
that revascularisation should aim to improve perfusion to the foot as much as 
possible, which will vary according to the individual patient. As skin oxygen 
tension increases progressively in a period of several weeks after a successful 
PTA, TcPO2 measurements should preferably be performed at least 1-3 weeks 
after the procedure 61. 
  
Recommendation 12: As evidence is inadequate to establish whether an 
endovascular, open or hybrid revascularisation technique is superior, make 
decisions based on individual factors, such as morphological distribution of 
peripheral artery disease, availability of autogenous vein, patient co-morbidities 
and local expertise. (Strong; Low) 
 
Recommendation 13: Any centre treating patients with a diabetic foot ulcer 
should have expertise in, and rapid access to facilities necessary to diagnose and 
treat, PAD, including both endovascular techniques and bypass surgery. (Strong; 
Low)  
 
Recommendation 14: Ensure that after a revascularisation procedure in a 
patient with a diabetic foot ulcer, the patient is treated by a multidisciplinary team 
as part of a comprehensive care plan. (Strong; Low) 
 
Recommendation 15: Urgently assess and treat patients with signs or symptoms 
of peripheral artery disease and a diabetic foot infection, as they are at particularly 
high risk for major limb amputation. (Strong; Moderate) 
 
Rationale 
There is still no consensus on the most appropriate approach to revascularisation 
in a patient with diabetes and foot ulceration. In our systematic review, we found 
that the major outcomes of wound healing and amputation were broadly similar 
between endovascular and open interventions22. Each of these techniques has its 
advantages and disadvantages. A successful distal venous bypass can result in a 
marked increase of blood flow to the foot but general anaesthesia is usually 
necessary and a suitable vein, as a bypass conduit, should be present. An 
endovascular procedure has several logistical advantages but sometimes very 
complex interventions are necessary to obtain adequate blood flow in the foot and 
a failed endovascular intervention may lead to worse outcomes when an open 
procedure is subsequently performed 62. Over the past few decades, there have 
been significant advancements in endovascular techniques, however parallel to 
this, we have seen improvements in anaesthesia and peri-operative care that have 
helped improve surgical outcomes. Whilst the BASIL trial is often quoted as a 
guide to revascularisation of patients with limb ischaemia 63, the cohort included 
a small proportion of patients with diabetes, of which there was no sub-group 
analysis, and was not focused on patients with ulceration. Therefore, we cannot 
extrapolate these findings to our patients with diabetes, foot ulceration and PAD. 
Finally, it is becoming increasingly common to adopt a combined open and 
endovascular (hybrid) approach. Therefore, we recommend that in each patient 
requiring lower-limb revascularisation, an endovascular, an open procedure and 
a hybrid procedure should be considered. As there is no ‘one-fits-all’ approach to 
treatment for patients with diabetes, foot ulceration and PAD, it is important that 
a treating centre has the expertise and facilities to provide a range of treatment 
options with availability of both endovascular and open methods. 
 
As discussed in other parts of the IWGDF Guidance, restoration of perfusion in the 
foot is only part of the treatment, which should be provided by multi-disciplinary 
care team 64. Any revascularisation procedure should therefore be part of a 
comprehensive care plan that addresses other important issues including: prompt 
treatment of concurrent infection, regular wound debridement, biomechanical 
off-loading, control of blood glucose and treatment of co-morbidities 64. In 
particular, patients with a foot infection are at high risk for limb loss and should 
be treated as a medical emergency. The 1-year major amputation rate for such 
patients has been reported to be as high as 44% 65 and delay in treatment can lead 
to rapid tissue destruction and life-threatening sepsis 66 as described in our 
guidelines on infection. In patients with deep infection, such as a foot abscess, 
infection of deep a foot compartment that needs immediate drainage or extensive 
tissue loss/ gangrene that must be removed to control the infection, immediate 
drainage should be considered first, in order to control sepsis 14. As described in 
our Infection Guidelines, this should be accompanied by aggressive antibiotic 
therapy, initially broad-spectrum, and rationalised according to tissue culture 14 - 
‘time is tissue’ in these patients. Once the sepsis is controlled and the patient is 
stabilised, evaluation of the arterial tree should lead to consideration for prompt 
revascularisation (ie within a few days). Once blood flow is improved and 
infection is treated, a definitive operation may be required in order to create a 
functional foot, which may require soft tissue and bone reconstruction. In patients 
with severely impaired perfusion and severe tissue loss, but without infection, 
extensive debridement or amputation of part of the foot should preferably not be 
performed until perfusion is restored.  
 
 
PICO: In a patient with a diabetic foot ulcer and PAD are there any circumstances 
in which revascularisation should not be performed? 
 Recommendation 16: Avoid revascularisation in patients in whom, from the 
patient’s perspective, the risk–benefit ratio for the probability of success of the 
procedure is unfavourable. (Strong; Low) 
 
Rationale 
Revascularisation should not be performed if there is no realistic chance of wound 
healing, or when major amputation is inevitable. Many patients pose high 
anaesthetic risk due to comorbidities and major reconstructive surgery confers 
significant risk of peri-operative complications. In particular, the following 
patients may not be suitable for revascularisation: those who are very frail, have 
short life expectancy, poor functional status, are bed bound, have a large area of 
tissue destruction that renders the foot functionally unsalvageable, and those who 
cannot realistically be expected to mobilise following revascularisation. The 
decision to proceed to primary amputation, or to adopt a palliative approach, 
should be made in conjunction with the patient and a multi-disciplinary team that 
includes a vascular surgeon or another specialist with expertise in vascular 
interventions 67. 
 
In those patients in whom the risk-benefit ratio of revascularisation is unclear, it 
should be taken into account that some severely ischaemic ulcers heal without 
revascularisation - two observational studies demonstrated healing rates of 
around 50% (with or without minor amputations) in patients unsuitable (either 
because they were deemed too frail or where revascularisation was not 
technically possible) for revascularisation 10. 
 
There are several other techniques that have been investigated for patients with 
diabetes, PAD and ulceration in whom there are no options for revascularisation. 
These include venous arterialisation and intermittent pneumatic compression 
therapy. 68 69. However, there are insufficient data to provide any recommendation 
on their utility in patients where no revascularisation option exists.  
 
PICO: In patients with diabetes, foot ulceration and PAD, is it possible to reduce 
the risk of future cardiovascular events? 
Recommendation 17: Provide intensive cardiovascular risk management for any 
patient with diabetes and an ischaemic foot ulcer, including support for cessation 
of smoking, treatment of hypertension, control of glycaemia and treatment with a 
statin drug as well as low-dose clopidogrel or aspirin. (Strong; Low)  
 
Rationale 
Patients with diabetes, PAD and ulceration have an overall 5-year mortality of 
around 50% due to the markedly increased risk of cardiovascular events 70. In line 
with other guidelines 26 25, we recommend prompt and thorough management of 
other cardiovascular risk factors in patients with diabetes and PAD.  
 
Patients should receive support to stop smoking and should maintain their blood 
pressure and blood glucose according to hypertension and diabetes guidelines 
recommendations. In addition, all patients should be prescribed a statin and anti-
platelet therapy. This strategy has been shown to reduce the 5-year mortality in 
patients with neuro-ischaemic ulcers 71. There is no specific evidence supporting 
the most appropriate anti-platelet agent in patients with diabetes, PAD and 
ulceration, however a number of recent guidelines have favoured clopidogrel over 
aspirin in the management of patients with PAD 26. A sub-analysis of a recent trial 
of anti-platelets and anti-coagulation suggested that the combination of aspirin 
and the direct oral anticoagulant rivaroxaban was more effective at reducing 
major limb events when compared to aspirin alone in patients with PAD, however 
this strategy was at the expense of an increase in (non-fatal) bleeding events 72. 
Although 45% had diabetes, no information was provided about the presence of a 
foot ulcer and the outcomes of these patients were not reported separately. 
It should be noted that we did not address the effect of lipid lowering therapies, 
blood glucose lowering medication or anticoagulant therapies on wound healing 
and amputation, as we felt that the evidence in these areas is still too limited. 
 
FUTURE RESEARCH PRIORITIES 
Our systematic reviews have demonstrated that that there is a paucity of 
contemporary high-quality data concerning the specific sub group of patients with 
diabetes, ulceration and PAD. 73. Further research is required in order to address 
the issues surrounding the appropriate management, including diagnosis, 
prognosis and deciding whether, when and how to revascularise. The IWGDF and 
EWMA published in 2016 the core details required in the planning and reporting 
of intervention studies in the prevention and management of diabetic foot ulcers, 
including those with PAD 16. These guidelines can serve as a roadmap to increase 
the quality of studies published in this area.  
In addition, there are a number of other key areas of interest that deserve further 
attention: 
 
- What is the natural history of the diabetic foot ulcer with PAD with optimal 
conservative treatment?  
- What is the optimal combination of diagnostic tests to predict healing in 
patient with a diabetic foot ulcer and PAD 
- What is the role of novel methods of perfusion assessment (including the 
microcirculation) to inform the decision to revascularise patients with 
diabetic foot ulceration and PAD? 
- Is there any role for pre-emptive revascularisation in patients with 
diabetes with intact feet who are at high risk for ulceration / amputation? 
- Is angiosome-directed revascularisation more effective than a best vessel 
approach in patients with diabetic foot ulceration? 
- Is venous arterialisation effective in healing ulcers or preventing 
amputation in people who are not appropriate for standard 
revascularisation? 
- Are novel medical therapies including stem cells or peripheral blood 
mononuclear cells effective in healing patients with DFU and PAD where 
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